Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON (Reuters) – For Christophe Weber, the boss of Japan’s Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

Source: Reuters

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>